Trials / Recruiting
RecruitingNCT07217678
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- University of Miami · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Durysta, Bimatoprost Intracameral Implant 10 µg | Participants in this arm will receive a one-time injection of Durysta (intracameral bimatoprost 10mcg). Participants will be followed by a total of 3 months. |
Timeline
- Start date
- 2026-02-09
- Primary completion
- 2028-01-31
- Completion
- 2028-01-31
- First posted
- 2025-10-16
- Last updated
- 2026-03-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07217678. Inclusion in this directory is not an endorsement.